Theriva Biologics

Theriva Biologics (TOVX) Stock Surges on Cancer Trial Breakthrough – What’s Next?

Theriva’s Stock Swing: In mid-October, Theriva’s Nasdaq-traded shares spiked on news of clinical success. On Oct. 15 the stock jumped from roughly $0.44 to $0.84 intraday ts2.tech, an increase of about 92%. This surge coincided with reports that VCN-01 had met the primary endpoints in the VIRAGE Phase 2b trial (see below). The very next trading day, Theriva disclosed a $4.0 million warrant inducement financing. Investors exercising warrants at $0.54 per share provided immediate cash ts2.tech, but the announcement also trimmed the earlier stock rally – TOVX settled in the mid-$0.40 range by Oct. 16 ts2.tech ts2.tech. In the days

24 October 2025

Theriva Biologics Stock Skyrockets 92% on Cancer Trial Breakthrough – What’s Next for TOVX?

Recent Clinical Developments and Pipeline Updates Theriva Biologics – a Rockville, MD-based clinical-stage biotech – has made headlines with promising cancer trial results. On October 13, 2025, the company announced that expanded data from its VIRAGE Phase 2b trial in metastatic pancreatic ductal adenocarcinoma will be presented at the ESMO 2025 Congress on Oct. 20 ts2.tech. In this trial, patients receiving VCN-01 (an oncolytic adenovirus therapy) plus standard gemcitabine/nab-paclitaxel chemo showed markedly better outcomes than chemo alone. Interim data filed with the SEC reveal VCN-01 improved median overall survival to around 11–14 months versus ~8–11 months for chemo-only patients ts2.tech.

16 October 2025

Biotech News · Cancer Research · Investment Insights · Pharma Updates · Stock Market